Measurable Residual Disease-Guided Therapy Promising in CLL

The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.

Related Keywords

United States ,United Kingdom ,Miami ,Florida ,American ,Mikkaela Sekeres ,Lee Greenberger ,University Of Miami Miller School Medicine ,American Society Of Hematology ,Leukemia Lymphoma Society ,Peter Hillmen ,Leeds Institute ,Medical Research ,University Hospital ,American Society ,New England Journal ,Miami Miller School ,Medscape Medical News ,Chronic Lymphocytic Leukemia Lymphoid Cll Leukaemia ,Immunotherapy ,Leukemia Leukaemia Blood Cancer ,Biologic Therapy ,Iologics ,Myelodysplastic Syndrome Mds Myelodysplasia ,Targeted Therapy ,Targeted Cancer Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Antineoplastic Drug ,